Literature DB >> 25986917

Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis.

Emilie Lund Egsmose1, Ole Rintek Madsen.   

Abstract

The interplay between patient-reported outcome measures in rheumatology is not well clarified. The objective of the study was to examine associations on the group level and concordance on the individual patient level between patient global assessment (PaGl), pain, and fatigue as scored on visual analog scales (VAS) in the daily clinic by patients with active rheumatoid arthritis (RA). Associations with other measures of disease activity were also examined. Traditional disease activity data on 221 RA patients with active disease planned to initiate biological treatment were extracted from the Danish DANBIO registry. Associations between VAS PaGl, pain, and fatigue (0-100) were examined using multiple regression analysis. Concordance between the VAS scores was expressed as the bias (mean difference between intra-individual scores) and the 95% lower and upper limits of agreement (LLoA; ULoA) according to the Bland-Altman method. Mean age was 57 ± 14 years, mean Disease Activity Score (DAS28-CRP4) 5.0 ± 0.9, and mean PaGl 63.6 ± 22.6. PaGl was most strongly predicted by pain and fatigue, pain by PaGl and fatigue, and fatigue by PaGl and pain (beta ranging from 0.17 to 0.69, p < 0.01-0.0001). More objective measures were not or far less predictive. LLoA;ULoA [bias] for PaGl vs. pain was -19.1; 29.5 [5.2], for PaGl vs. fatigue -22.8; 28.6 [2.9], and for fatigue vs. pain -29.2; 33.8 [2.3]. In conclusion, PaGl, pain, and fatigue were most strongly explained by each other, not by more objective clinical measures of disease activity and were nearly identical on the group level. On the individual patient level, however, differences between the scores varied considerably. The findings highlight the challenge of understanding and dealing with traditional patient-reported VAS measures when it comes to individual RA patients in the daily clinic.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986917     DOI: 10.1007/s10067-015-2968-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  42 in total

1.  Coping Styles, Pain Expressiveness, and Implicit Theories of Chronic Pain.

Authors:  N C Higgins; S Jeffrey Bailey; Diane L LaChapelle; Katherine Harman; Thomas Hadjistavropoulos
Journal:  J Psychol       Date:  2014-11-14

Review 2.  Quantitative joint assessment in rheumatoid arthritis.

Authors:  T Sokka; T Pincus
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

3.  The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis.

Authors:  Richard Charles John Campbell; Michael Batley; Anthony Hammond; Fowzia Ibrahim; Gabrielle Kingsley; David L Scott
Journal:  Clin Rheumatol       Date:  2011-11-29       Impact factor: 2.980

4.  Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents.

Authors:  Shino Yuasa; Harutaka Yamaguchi; Yoshinori Nakanishi; Shingo Kawaminami; Ryo Tabata; Nobuhiko Shimizu; Mitsuhiro Kohno; Teruki Shimizu; Junya Miyata; Mayuko Nakayama; Jun Kishi; Yuko Toyoda; Yasuhiko Nishioka; Kenji Tani
Journal:  J Med Invest       Date:  2013

5.  Predictors of subjective fatigue among individuals with rheumatoid arthritis.

Authors:  B A Huyser; J C Parker; R Thoreson; K L Smarr; J C Johnson; R Hoffman
Journal:  Arthritis Rheum       Date:  1998-12

6.  Factors related to fatigue in women and men with early rheumatoid arthritis: the Swedish TIRA study.

Authors:  Ingrid Thyberg; Orjan Dahlström; Mikael Thyberg
Journal:  J Rehabil Med       Date:  2009-11       Impact factor: 2.912

Review 7.  Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP).

Authors:  Gillian A Hawker; Samra Mian; Tetyana Kendzerska; Melissa French
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

8.  Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials.

Authors:  Theodore Pincus; Ingrid Amara; Oscar G Segurado; Martin Bergman; Gary G Koch
Journal:  J Rheumatol       Date:  2007-11-15       Impact factor: 4.666

9.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Authors:  Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hansen; Ib Tønder Hansen; Gina Kollerup; Louise Linde; Hanne M Lindegaard; Uta Engling Poulsen; Annette Schlemmer; Dorte Vendelbo Jensen; Signe Jensen; Gisela Hostenkamp; Mikkel Østergaard
Journal:  Arthritis Rheum       Date:  2010-01

10.  What are the essential elements to enable patient participation in medical decision making?

Authors:  Liana Fraenkel; Sarah McGraw
Journal:  J Gen Intern Med       Date:  2007-05       Impact factor: 5.128

View more
  8 in total

1.  What Does the Patient Global Health Assessment in Rheumatoid Arthritis Really Tell Us? Contribution of Specific Dimensions of Health-Related Quality of Life.

Authors:  Ethan T Craig; Jamie Perin; Scott Zeger; Jeffrey R Curtis; Vivian P Bykerk; Clifton O Bingham; Susan J Bartlett
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11       Impact factor: 4.794

2.  Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic.

Authors:  Ole Rintek Madsen; Eva Marie Egsmose
Journal:  Rheumatol Int       Date:  2016-07-23       Impact factor: 2.631

3.  Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria.

Authors:  Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2016-06-09       Impact factor: 2.980

4.  Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis.

Authors:  Lisanne Renskers; Ron J J C van Uden; Anita M P Huis; Sanne A A Rongen; Steven Teerenstra; Piet L C M van Riel
Journal:  Clin Rheumatol       Date:  2018-09-12       Impact factor: 2.980

5.  Relationship between daily pain and affect in women with rheumatoid arthritis: lower optimism as a vulnerability factor.

Authors:  Zuzanna Kwissa-Gajewska; Ewa Gruszczyńska
Journal:  J Behav Med       Date:  2017-07-17

6.  A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review.

Authors:  Rinie Geenen; Emma Dures
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

7.  Defining the relationship between pain intensity and disease activity in patients with rheumatoid arthritis: a secondary analysis of six studies.

Authors:  Fowzia Ibrahim; Margaret Ma; David L Scott; Ian C Scott
Journal:  Arthritis Res Ther       Date:  2022-09-10       Impact factor: 5.606

8.  Remission or Not Remission, That's the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis.

Authors:  Alen Brkic; Katarzyna Łosińska; Are Hugo Pripp; Mariusz Korkosz; Glenn Haugeberg
Journal:  Rheumatol Ther       Date:  2022-09-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.